Ligand (LGND) Q1 Earnings & Sales Fall Y/Y, Stock Down
Zacks Investment Research | May 03, 2019 08:42AM ET
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) reported first-quarter 2019 adjusted earnings of $1.16 per share, down from the year-ago figure of $1.55. Adjusted earnings exclude the impact of one-time tax gain of $640 million related to sales of Promacta rights. Including this gain, the company reported earnings of $31.32 per share. The Zacks Consensus Estimate was $28.42.
In March, Ligand industry ’s 13.8% decrease.
Total revenues in the quarter decreased to $43.2 million from $56.2 million in the year-ago period. However, the top line surpassed the Zacks Consensus Estimate of $38.31 million.
Quarterly Highlights
Royalty revenues were $19.5 million in the reported quarter, down approximately 6.3% year over year. Ligand primarily earns royalties on sales of Novartis' (NYSE:NVS) Promacta, Amgen's (NASDAQ:AMGN) Kyprolis and CASI Pharmaceuticals' (NASDAQ:CASI) Evomela, which were developed using its Captisol technology.
License fees, milestones and other revenues were $15 million in the first quarter compared with $30.9 million in the year-ago period. The company had recorded an upfront milestone payment related to the out-licensing of its glucagon receptor antagonist program to Roivant Sciences in year-ago quarter.
Material sales were $9 million compared with $4.4 million in the year-ago quarter due to the favorable timing of Captisol purchases for clinical and commercial use.
Ligand announced completion of enrollment in a phase I study evaluating its internal Captisol-enabled Iohexol program. Top-line data is expected in the third quarter of 2019.
Business Developments
During the quarter, Ligand completed six new deals related to its OmniAb and Captisol technology platforms. It also acquired a new technology company, Dianomi. Moreover, a drug developed using Ligand’s technology received approval and the first OmniAb partnered program entered late-stage development.
In March, Sage Therapeutics received approval from the FDA for its postpartum depression drug, Zulresso. Zulresso has been developed using Ligand’s Captisol technology. Ligand received $3 million in milestone payment following the approval. The drug will be launched in June this year, which may generate potential royalties for Ligand.
2019 Guidance Maintained
Ligand reiterated its guidance for 2019 following the completion of sale of Promacta rights. It expects revenues to be approximately $118 million including royalties of nearly $48 million, material sales of roughly $27 million and license fees and milestones of almost $43 million. Adjusted earnings, excluding one-time gain from Promacta sale, are estimated to be $3.20 per share for 2019.
Get The News You Want
Ligand Pharmaceuticals Incorporated Price, Consensus and EPS Surprise
Zacks Investment Research
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.